For the fifth year in a row, use of most substances among teenagers in the United States remains near the low point reached in 2021. The finding comes from the Monitoring the Future survey at the University of Michigan. The survey is done every year and has had support from the National Institutes of Health for many years.
The survey asks eighth, tenth and twelfth graders about substance use in the past month and year, and about harm and availability. In 2025 most measures stayed about the same as in 2024. Investigators collected answers from many schools and made the results representative for the whole country.
Difficult words
- substance — a chemical, drug, or material people can usesubstances
- survey — a study that asks people questions
- harm — physical or mental damage or hurt
- availability — how easy something is to get
- representative — true for the larger group or population
- investigator — a person who studies facts and collects informationInvestigators
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is it useful that the survey is done every year?
- How might collecting answers from many schools help the results?
- Do you think questions about harm and availability are important? Why or why not?
Related articles
New oral drug approved for sleeping sickness
European regulators approved Acoziborole, a single-dose oral treatment for sleeping sickness after successful trials in the DRC and Guinea. Sanofi will donate doses to WHO, but national approvals and vector control are still needed to reach elimination goals.
AI expands sexual and reproductive health information in Peru and Argentina
Health groups in Peru and Argentina use artificial intelligence to give sexual and reproductive health information to young and marginalised people. Projects include a Quechua chatbot and a WhatsApp platform, but experts warn of bias and access problems.
AI and Wearable Devices for Type 2 Diabetes
A meta-review from the University at Buffalo examines AI-enhanced wearable devices for Type 2 diabetes and prediabetes. The study finds predictive benefits and important limits, and calls for larger, more transparent studies before routine clinical use.
